scholarly journals Inhibitory Effects of Onion (Allium cepa L.) Extract on Proliferation of Cancer Cells and Adipocytes via Inhibiting Fatty Acid Synthase

2012 ◽  
Vol 13 (11) ◽  
pp. 5573-5579 ◽  
Author(s):  
Yi Wang ◽  
Wei-Xi Tian ◽  
Xiao-Feng Ma
Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1132
Author(s):  
Javier A. Menendez ◽  
Adriana Papadimitropoulou ◽  
Travis Vander Steen ◽  
Elisabet Cuyàs ◽  
Bharvi P. Oza-Gajera ◽  
...  

The identification of clinically important molecular mechanisms driving endocrine resistance is a priority in estrogen receptor-positive (ER+) breast cancer. Although both genomic and non-genomic cross-talk between the ER and growth factor receptors such as human epidermal growth factor receptor 2 (HER2) has frequently been associated with both experimental and clinical endocrine therapy resistance, combined targeting of ER and HER2 has failed to improve overall survival in endocrine non-responsive disease. Herein, we questioned the role of fatty acid synthase (FASN), a lipogenic enzyme linked to HER2-driven breast cancer aggressiveness, in the development and maintenance of hormone-independent growth and resistance to anti-estrogens in ER/HER2-positive (ER+/HER2+) breast cancer. The stimulatory effects of estradiol on FASN gene promoter activity and protein expression were blunted by anti-estrogens in endocrine-responsive breast cancer cells. Conversely, an AKT/MAPK-related constitutive hyperactivation of FASN gene promoter activity was unaltered in response to estradiol in non-endocrine responsive ER+/HER2+ breast cancer cells, and could be further enhanced by tamoxifen. Pharmacological blockade with structurally and mechanistically unrelated FASN inhibitors fully impeded the strong stimulatory activity of tamoxifen on the soft-agar colony forming capacity—an in vitro metric of tumorigenicity—of ER+/HER2+ breast cancer cells. In vivo treatment with a FASN inhibitor completely prevented the agonistic tumor-promoting activity of tamoxifen and fully restored its estrogen antagonist properties against ER/HER2-positive xenograft tumors in mice. Functional cancer proteomic data from The Cancer Proteome Atlas (TCPA) revealed that the ER+/HER2+ subtype was the highest FASN protein expressor compared to basal-like, HER2-enriched, and ER+/HER2-negative breast cancer groups. FASN is a biological determinant of HER2-driven endocrine resistance in ER+ breast cancer. Next-generation, clinical-grade FASN inhibitors may be therapeutically relevant to countering resistance to tamoxifen in FASN-overexpressing ER+/HER2+ breast carcinomas.


2010 ◽  
Vol 6 (1) ◽  
pp. 63-69 ◽  
Author(s):  
Maria Notarnicola ◽  
Simona Pisanti ◽  
Valeria Tutino ◽  
Domenica Bocale ◽  
Maria Teresa Rotelli ◽  
...  

The Prostate ◽  
2007 ◽  
Vol 67 (10) ◽  
pp. 1111-1120 ◽  
Author(s):  
Lucy J. Schmidt ◽  
Karla V. Ballman ◽  
Donald J. Tindall

RSC Advances ◽  
2018 ◽  
Vol 8 (15) ◽  
pp. 8112-8117 ◽  
Author(s):  
Yan Liang ◽  
Di Luo ◽  
Xuan Gao ◽  
Hao Wu

Garcinone E exhibits both fast-binding reversible and time-dependent irreversible inhibition on the activity of fatty acid synthase.


2007 ◽  
Vol 109 (3) ◽  
pp. 471-479 ◽  
Author(s):  
Teresa Puig ◽  
Alejandro Vázquez-Martín ◽  
Joana Relat ◽  
Jordi Pétriz ◽  
Javier A. Menéndez ◽  
...  

2010 ◽  
Vol 12 (6) ◽  
Author(s):  
Quanri Jin ◽  
Linda X Yuan ◽  
Delphine Boulbes ◽  
Jong Min Baek ◽  
Ying Nai Wang ◽  
...  

2019 ◽  
Vol 464 (1-2) ◽  
pp. 11-20 ◽  
Author(s):  
Li Xiu Xu ◽  
Li Jun Hao ◽  
Jun Qi Ma ◽  
Jing Kun Liu ◽  
Ayshamgul Hasim

2012 ◽  
Vol 48 (2) ◽  
pp. 182-192 ◽  
Author(s):  
Hiu-Yee Kwan ◽  
Zhijun Yang ◽  
Wang-Fun Fong ◽  
Yong-Mei Hu ◽  
Zhi-Ling Yu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document